Janus kinase inhibition as a potential strategy for the treatment of psoriasis: State of the art and future perspectives

Journal of Biological Regulators and Homeostatic Agents

Volumn 26, Issue 4, 2012, Pages 587-596

  Cassano, N ^a   Vena, Gino A ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Immunosuppression; JAK STAT signaling; Janus kinases; Psoriasis; Ruxolitinib; Tofacitinib; Treatment

Indexed keywords

ALPHA INTERFERON; ASP 015K; ATORVASTATIN; BARICITINIB; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 20; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; PLACEBO; PRODRUG; PROTEIN KINASE TYK2; R 348; RUXOLITINIB; TOFACITINIB; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANEMIA; B LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; DRUG POTENCY; ENZYME INHIBITION; ERYTHROPOIESIS; GRANULOPOIESIS; HEADACHE; HEMATOPOIETIC CELL; HUMAN; IMMUNE SYSTEM; KERATINOCYTE; LEUKOPENIA; NATURAL KILLER CELL; NAUSEA; NONHUMAN; PATHOGENESIS; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THROMBOCYTOPENIA; THYMOCYTE; TRIACYLGLYCEROL BLOOD LEVEL; DRUG ANTAGONISM; ENZYMOLOGY;

HUMANS; JANUS KINASES; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRAZOLES; PYRIMIDINES; PYRROLES;

EID: 84876465957     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus kinases. Immunol Rev 2008; 223:132-42. (Pubitemid 351986189)
2. Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochem Pharmacol 2012; 1;83(9):1136-45
3. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003; 31:900-11. (Pubitemid 37411719)
4. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282:20059-63. (Pubitemid 47099977)
5. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007; 178:2623-9. (Pubitemid 46333135)
6. Ghoreschi K, Laurence A, O'Shea J. Janus kinases in immune cell signaling. Immunol Rev 2009; 228:273-87.
7. Jatiani SS, Baker SJ, Silverman LR, Reddy EP. JAK/STAT pathways in cytokine signaling and myeloproliferative disorders: Approaches for targeted therapies. Genes Cancer 2011; 1:979-93.
8. Zouein FA, Duhé RJ, Booz GW. JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth. Growth Factors 2011; 29:245-52.
9. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010; 24:513-26.
10. Vijayakrishnan L, Venkataramanan R, Gulati P. Treating inflammation with the Janus Kinase inhibitor CP-690,550. Trends Pharmacol Sci 2011; 32:25-34.
11. Nosaka T, vanDeursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science 1995; 270:800-2.
12. Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol 2011; 131:1838-44.
13. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93:385-95. (Pubitemid 28232083)
14. Neubauer H, Cumano A, Mueller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998; 93:397-409. (Pubitemid 28232084)
15. Garber K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol 2011; 29:467-8.
16. Wagner M, Siddiqui MA. Signaling networks regulating cardiac myocyte survival and death. Curr Opin Investig Drugs 2009; 10:928-37.
17. Mak RK, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr 2009; 100(2):2-13.
18. Jabbari A, Johnson-Huang LM, Krueger JG. Role of the immune system and immunological circuits in psoriasis. G Ital Dermatol Venereol 2011; 146:17-30.
19. Zhou X, Krueger J, Kao M, Lee E, Du F, Menter A, Wong WH, Bowcock AM. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003; 13:69-78. (Pubitemid 37129170)
20. van der Fits L, van der Wel L, Laman J, Prens E, Verschuren M. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol 2004; 122:51-60. (Pubitemid 38114638)
21. Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005; 11:43-9. (Pubitemid 40215836)
22. Sano S, Chan KS, DiGiovanni J. Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases. J Dermatol Sci 2008; 50:1-14. (Pubitemid 351249893)
23. Schindler C, Plumlee C. Interferons pen the JAK-STAT pathway. Semin Cell Dev Biol 2008; 19:311-8.
24. Tonel G, Conrad C. Interplay between keratinocytes and immune cells - recent insights into psoriasis pathogenesis. Int J Biochem Cell Biol 2009; 41:963-8.
25. Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 2009; 8:40-52.
26. Zhang N, Pan HF, Ye DQ. Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol Cell Biochem 2011; 353:41-6.
27. Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010; 184:5298-307.
28. Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol 2009; 183:2183-92.
29. Vena GA, Cassano N. New agents in development. In: S.R. Feldman, ed. Current and emerging treatment for psoriasis. Future Medicine Ltd. London, 2011; pp. 100-21.
30. http://www.clinicaltrials.gov
31. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 115:3109-17.
32. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nature Rev 2011; 10:127-40.
33. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011; 86: 1188-91.
34. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs 2010; 13: 394-403.
35. Punwani N, Scherle P, Flores R, Shi et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 2012 Jan 24. [Epub ahead of print]
36. Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010; 53: 8468-84.
37. Jiang JK, Ghoreschi K, Deflorian F, et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3- (methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl) -3-oxopropanenitrile (CP-690,550). J Med Chem 2008; 51:8012-8.
38. Williams NK, Bamert RS, Patel O, et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol 2009; 387:219-32.
39. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26:127-32.
40. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010; 7:41.
41. Liu EH, Siegel RM, Harlan DM, O'Shea JJ. T cell-directed therapies: lessons learned and future prospects. Nat Immunol 2007; 8:25-30. (Pubitemid 46242355)
42. [No authors listed] Tasocitinib. Drugs RD 2010; 10:271-84.
43. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186: 4234-43.
44. van Gurp EA, Schoordijk-Verschoor W, Klepper M, Korevaar SS, Chan G, Weimar W, Baan CC. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 2009; 87:79-86.
45. brightFoxP3+ regulatory T cells and inhibits effector T cells. Am J Transplant 2010; 10:1785-95.
46. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008; 28:477-87. (Pubitemid 351467044)
47. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH; Tofacitinib Study Investigators.Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011; 63:1150-8.
48. Fleischmann R, Cutolo M, Genovese MC, et al. Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs. Arthritis Rheum 2012; 64:617-29.
49. Kremer JM, Cohen S, Wilkinson BE, et al. A Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone. Arthritis Rheum 2012; 64:970-81.
50. McInnes I, Kim HY, Lee SH, et al. Phase 2 study of the effects of open-label CP-690,550 and double-blind atorvastatin on lipids in patients with active rheumatoid arthritis. Ann Rheum Dis 2011; 70:169.
51. Connell C, Fleischmann R, Kremer J, Benda B, Bradley J, Gruben D, Zwillich SH, Kanik KS. Phase 3 Study of oral JAK inhibitor CP-690,550 monotherapy in patients with active rheumatoid arthritis: subanalysis of efficacy. Ann Rheum Dis 2011; 70:600.
52. Kremer J, Li ZG, Hall S, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with traditional DMARDs: a Phase 3 efficacy and safety study in patients with active rheumatoid arthritis with an inadequate response to DMARDs. Ann Rheum Dis 2011; 70:170.
53. Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol 2009; 129:2299-302.
54. West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 2009; 10:491-504.
55. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167:668-77.
56. Papp K, Menter A, Harness J, Tan H. Tasocitinib (CP-690,550), an oral Janus kinase inhibitor, consistently improves the clinical signs of moderate-to-severe psoriasis in different body regions. J Am Acad Dermatol 2011; 64(1):AB153.
57. Mamolo C, Bushmakin AG, Cappelleri JC, Harness J, Stewart M, Tan H. The itch severity item: mediation modeling and measurement characteristics from a phase 2b trial of tasocitinib (CP-690,550), an oral Janus kinase inhibitor, in patients with plaque psoriasis. J Am Acad Dermatol 2011; 64(2 Suppl 1):AB152.
58. Gupta P, Chapel S, Krishnaswami S, Buonanno M, Harness J. Population pharmacokinetics of tasocitinib (CP-690,550) in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2011; 64(1):AB163.